by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Dementia
Abstract INTRODUCTION Real-world data on lecanemab’s efficacy and the longitudinal dynamics of plasma biomarkers are scarce in Chinese patients with Alzheimer’s disease (AD). METHODS In this multicenter cohort study, 181 AD patients received biweekly...
by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Dementia
Abstract The Brains for Dementia Research (BDR) project was established to provide high quality, neuropathologically characterized post-mortem brain tissue from a cohort of participants longitudinally assessed for outcomes that are relevant for research in relation to...
by Clinical Neuropsychologist Online | Monday, October 26, 2026 | Dementia
Abstract Alzheimer’s disease (AD) is the leading cause of dementia worldwide, yet clinical trials remain unrepresentative of those most affected. Ethnic minoritized groups, socioeconomically deprived communities, adults over 75, and populations in low- and...
by Clinical Neuropsychologist Online | Monday, October 26, 2026 | Dementia
Alzheimer’s &Dementia, Volume 22, Issue 10, October 2026. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | October 26, 2026 Neuro-Dementia...
by Clinical Neuropsychologist Online | Monday, October 26, 2026 | Dementia
Abstract BACKGROUND Individuals with Alzheimer’s disease (AD) dementia can be subgrouped based on cognitive performance at diagnosis. We compared neuropathology across cognitively defined AD subgroups in the Adult Changes in Thought study. METHODS Scores for...
by Clinical Neuropsychologist Online | Monday, October 26, 2026 | Dementia
Abstract INTRODUCTION Dementia with Lewy bodies (DLB) is a common but underdiagnosed neurodegenerative disease associated with α-synuclein pathology. Clinically, DLB is characterized by early motor dysfunction and psychiatric symptoms, in contrast to early memory...
